TLP
EGRX

Tri Locum Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Tri Locum Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-122,503
Closed -$6.83M – 55
2021
Q3 		$6.83M Buy
122,503
+27,581
+29% +$1.36M 2.72% 15
2021
Q2 		$4.06M Buy
+94,922
New +$3.92M 1.33% 21

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Tri Locum Partners's EGRX Position: Q4 2021 in Review

Tri Locum Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2021, closing a stake of 122,503 shares — an estimated $6.83M sold.

Tri Locum Partners first reported a position in EGRX in Q2 2021 and held it in 2 quarters. The position peaked at $6.83M in Q3 2021. 162 funds tracked by Wall St. Rank hold EGRX as of Q4 2021.

  • Tri Locum Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Tri Locum Partners sold 122,503 Eagle Pharmaceuticals, Inc. shares in Q4 2021, an estimated $6.83M.
  • Tri Locum Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • Tri Locum Partners's Eagle Pharmaceuticals, Inc. position peaked at $6.83M in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2021.

Based on Tri Locum Partners's 13F filing for Q4 2021, filed 14 Feb 2022.